Clinical trial · Observational
Evaluation of CEMIP in Pancreatic Cancer
Evaluation of Cell Migration Inducing Protein (CEMIP) in Diagnosis of Pancreatic Carcinoma in Comparison With Other Traditional Markers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer (PC) is one of the most lethal diseases among all cancer types. The diagnosis of PC is usually based on radiology or invasive endoscopic techniques. Various types of tumor markers are used for diagnosing PC. The tumor markers carbohydrate antigen19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are the ones most closely tied to PC. These tests are more often used in people already diagnosed with pancreatic cancer to help tell if treatment is working or if the cancer is progressing . Cell migration inducing protein (CEMIP) has been reported to be associated with early detection, cancer cell migration, invasion, and poor prognosis. Aim of the work: * To Estimate the level of CEMIP, CA19-9 and CEA in pancreatic cancer patients. * To evaluate the clinical utility of serum CEMIP, CA19-9 and CEA in pancreatic cancer patients in comparison with healthy controls and their relation to cancer staging and histopathological types. * To detect the correlation between CEMIP, CA-19-9 and CEA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A) CBC . B) RBG. C)KFT. D) LFT. | Diagnostic Test | — | UNRESOLVED |
| CEMIP , CA19-9 ,CEA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1
- description
- pancreatic cancer patients (50 patients)
- interventionNames
- Diagnostic Test: CEMIP , CA19-9 ,CEA
- Diagnostic Test: A) CBC . B) RBG. C)KFT. D) LFT.
- label
- Group2
- description
- A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
- interventionNames
- Diagnostic Test: CEMIP , CA19-9 ,CEA
- Diagnostic Test: A) CBC . B) RBG. C)KFT. D) LFT.
Primary outcomes (1)
- measure
- Diagnostic value of cell migration inducing protein (CEMIP) in serum of pancreatic cancer as non invasive marker.
- timeFrame
- 2 day
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Group 1: Includes all patients presented by pancreatic cancer with clinical, radiological, laboratory diagnosis and pathological diagnosis. Group 2: A: Healthy individual B: Individual with benign diseases such as benign hepatopancreatobiliary conditions as gall stones, obstructive calcular jaundice, chronic pancreatitis and benign gasrtrointestinal as ulcer and polyp. Exclusion Criteria: * Patients recently operated for pancreatic cancer. * patients diagnosed to have another type of cancer (Breast, gastric or colorectal). * High risk group of another type of cancer. * Patients with disseminated cancer.
References
Publications (3)
- BACKGROUNDLee HS, Jang CY, Kim SA, Park SB, Jung DE, Kim BO, Kim HY, Chung MJ, Park JY, Bang S, Park SW, Song SY. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Sci Rep. 2018 Feb 21;8(1):3383. doi: 10.1038/s41598-018-21823-x. PMID 29467409
- BACKGROUNDKoga A, Sato N, Kohi S, Yabuki K, Cheng XB, Hisaoka M, Hirata K. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Pancreatology. 2017 Jan-Feb;17(1):115-122. doi: 10.1016/j.pan.2016.12.007. Epub 2016 Dec 18. PMID 28012880
- BACKGROUNDLi L, Yan LH, Manoj S, Li Y, Lu L. Central Role of CEMIP in Tumorigenesis and Its Potential as Therapeutic Target. J Cancer. 2017 Jul 20;8(12):2238-2246. doi: 10.7150/jca.19295. eCollection 2017. PMID 28819426